CSL closes on EU approval for haemophilia B gene therapy

CSL's gene therapy for haemophilia B has been recommended for approval by the EMA's human medicine committee, setting up a decision by the European Commission early next year.

uniQure, CSL claim first okay for haemophilia B gene therapy

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy fo

Trial sets up filings for uniQure's haemophilia gene therapy

Dutch biotech uniQure and partner CSL Behring are planning to file for approval of their gene therapy for haemophilia B, armed with new trial data that they say answers earlier concerns abo

FDA lifts hold on uniQure gene therapy after cancer case rev...

Dosing can start once again in uniQure's phase 3 trial of its haemophilia B gene therapy, after the FDA concluded that a case of liver cancer seen in the study was unlikely to be caused by

$2bn deal sees uniQure license haemophilia B gene therapy to...

UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the company exclusive global rights to uniQure’s gene therapy for haemophilia B. 

UniQure presses go on Huntington’s gene therapy trial